Comparison of the Pharmacologic Properties of the New Oral Anticoagulants | ||||
| CHARACTERISTIC | RIVAROXABAN | APIXABAN | EDOXABAN | DABIGATRAN |
|---|---|---|---|---|
| Target | Factor Xa | Factor Xa | Factor Xa | Thrombin |
| Prodrug | No | No | No | Yes |
| Bioavailability | 80% | 60% | 50% | 6% |
| Dosing | qd (bid) | bid | qd | bid (qd) |
| Half-life | 7-11 h | 12 h | 9-11 h | 12-17 h |
| Renal excretion | 33% (66%) | 25% | 35% | 80% |
| Interactions | CYP 3A4/P-gp | CYP 3A4/P-gp | P-gp | P-gp |